Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors
13 Oct 2023 //
ONCLIVE
Relay Therapeutics Announces RLY-4008 Data Showing Durable Responses Across Multiple FGFR2-Altered Solid Tumors
12 Oct 2023 //
GLOBENEWSWIRE
13 Oct 2023 //
ONCLIVE
12 Oct 2023 //
GLOBENEWSWIRE